red big swollen patch at the vaccination site; red big swollen patch at the vaccination site; red site is hot; red site is  itchy; This spontaneous case was reported by a physician and describes the occurrence of INJECTION SITE ERYTHEMA (red big swollen patch at the vaccination site), VACCINATION SITE SWELLING (red big swollen patch at the vaccination site), VACCINATION SITE WARMTH (red site is hot) and VACCINATION SITE PRURITUS (red site is  itchy) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination.     Concurrent medical conditions included Allergy to antibiotic ("most antibiotics"). Concomitant products included ATORVASTATIN and ACICLOVIR for an unknown indication.    On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INJECTION SITE ERYTHEMA (red big swollen patch at the vaccination site), VACCINATION SITE SWELLING (red big swollen patch at the vaccination site), VACCINATION SITE WARMTH (red site is hot) and VACCINATION SITE PRURITUS (red site is  itchy). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, INJECTION SITE ERYTHEMA (red big swollen patch at the vaccination site), VACCINATION SITE SWELLING (red big swollen patch at the vaccination site), VACCINATION SITE WARMTH (red site is hot) and VACCINATION SITE PRURITUS (red site is  itchy) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment for the events included cool compress. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 21-Jan-2021 and was forwarded to Moderna on 22-Jan-2021.    This spontaneous case was reported by a physician and describes the occurrence of INJECTION SITE ERYTHEMA (red big swollen patch at the vaccination site), VACCINATION SITE SWELLING (red big swollen patch at the vaccination site), VACCINATION SITE WARMTH (red site is hot) and VACCINATION SITE PRURITUS (red site is  itchy) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination.     Concurrent medical conditions included Allergy to antibiotic ("most antibiotics"). Concomitant products included ATORVASTATIN and ACICLOVIR for an unknown indication.    On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INJECTION SITE ERYTHEMA (red big swollen patch at the vaccination site), VACCINATION SITE SWELLING (red big swollen patch at the vaccination site), VACCINATION SITE WARMTH (red site is hot) and VACCINATION SITE PRURITUS (red site is  itchy). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, INJECTION SITE ERYTHEMA (red big swollen patch at the vaccination site), VACCINATION SITE SWELLING (red big swollen patch at the vaccination site), VACCINATION SITE WARMTH (red site is hot) and VACCINATION SITE PRURITUS (red site is  itchy) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment for the events included cool compress.